Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L‑4‑Chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (MDD)
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs AV 101 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors VistaGen Therapeutics
- 07 Mar 2018 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
- 07 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 15 Apr 2019.
- 07 Mar 2018 Status changed from not yet recruiting to recruiting.